Why The PAVmed (PAVM) Story Is Shifting After A Major Valuation Reset

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.

PAVmed is back in focus after analysts reset their fair value estimate from US$263.00 to US$40.50, a major shift that puts a very different marker on what they see as reasonable upside. Recent research links this change mainly to how models are being built and updated, rather than to one decisive new data point. This distinction matters for how you read the signal. As you read on, you will see what is driving the evolving narrative and how to keep track of it as conditions change.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value PAVmed.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

• Maxim continues to publish research on PAVmed, which signals ongoing interest in the story and a view that the shares still warrant a detailed valuation framework rather than being written off.

• Even after the revision, the new Maxim price target of US$40.50 still sits well above where many investors may mentally anchor the stock. The report can be read as a reset, not an abandonment, of the long term potential embedded in its models.

🐻 Bearish Takeaways

• Maxim lowered its PAVmed price target by US$44, which points to a reassessment of assumptions in key areas such as execution risks, timelines, or achievable market opportunity inside the firm's models.

• The size of the cut implies that Maxim sees a narrower gap between current trading levels and its estimate of fair value. Readers may want to treat upside scenarios with more caution and pay closer attention to how the thesis evolves with new data.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!

We've flagged 4 risks for PAVmed. See which could impact your investment.

What's in the News

• PAVmed relaunched its medical device portfolio under Mr. Virgilio, highlighting the PortIO implantable intraosseous vascular access device for rapid delivery of fluids and therapeutics into the bone marrow cavity and central venous circulation.

• The company licensed multi modality endoscopic imaging technology from Duke University into a new subsidiary, Octeris Inc., with plans to fund sponsored research aimed at improving detection and treatment of esophageal dysplasia during upper endoscopy.

• Stockholders approved an amendment to PAVmed's certificate of incorporation that allows removal of any director, with or without cause, by a majority of the outstanding voting power.

• PAVmed's auditor issued an unqualified opinion on the latest 10 K while expressing doubt about the company's ability to continue as a going concern. The company also closed a US$30,000,000 private placement of Series D Convertible Preferred Stock with attached warrants for up to an additional US$30,000,000.